PTGX News and Press, Protagonist Therapeutics Inc. From 10/09/23

ICONIC Phase 3 clinical program initiation in adults with moderate to severe plaque psoriasis ANTHEM Phase 2b initiation in ulcerative colitis Company is eligible to receive next two milestone payments for a total of $60M NEWARK, CA / ACCESSWIRE / October 9, 2023 / Protagonist Ther...

2023-09-22 15:35:32 ET Summary Protagonist Therapeutics, Inc.'s oral IL-23 drug for psoriasis, JNJ-2113, must show non-inferior efficacy to Johnson & Johnson's injectable Tremfya before further development. JNJ-2113 is the only oral IL-23 targeting molecule in development, but...

2023-09-22 10:15:25 ET FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 22, 2023 – USA News Group –  Despite the potential federal funding challenges due to the recent debt ceiling deal , optimism in the b...

NEWARK, CA / ACCESSWIRE / September 5, 2023 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in fireside chat presentations and host one-on-one meetings at the Well...

2023-09-04 02:56:19 ET Summary Protagonist Therapeutics focuses on peptide-based drugs, primarily rusfertide, which is undergoing a Phase 3 trial for polycythemia vera. Financially, PTGX is robust with $313.4M in assets and a cash runway of ~31 months; rusfertide shows significant...

2023-08-09 14:44:26 ET Summary Protagonist Therapeutics, Inc. is progressing with the use of its drug rusfertide for the treatment of polycythemia vera in a phase 3 study. The company expects to complete enrollment of the VERIFY study by Q1 2024 and release results in 2024. Pr...

Estimated cash runway now extended through Q1 2026 NEWARK, CA / ACCESSWIRE / August 9, 2023 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced it has received approximately $34.4 million in proceeds from the exercise of warrants to purchase 2.75 million...

2023-08-03 17:33:52 ET Protagonist press release ( NASDAQ: PTGX ): Q2 GAAP EPS of -$0.68 misses by $0.03 . Cash, Cash Equivalents and Marketable Securities: Cash, cash equivalents and marketable securities as of June 30, 2023, were $313.4 million. For further det...

Positive topline results from the Phase 2b FRONTIER 1 study of JNJ-2113 (formerly PN-235), the first and only IL-23 receptor antagonist oral peptide drug candidate for the treatment of moderate-to-severe plaque psoriasis, presented at the World Congress of Dermatology. JNJ-2113 now advances ...

2023-07-05 08:15:30 ET Impel Pharmaceuticals  ( IMPL ) +36% . Wolfspeed ( WOLF ) +18% enter 10-year silicon carbide wafer supply agreement. Nocera ( NCRA ) +12% . Digital World Acquisition  ( DWAC ) +10% reaches in-principle settleme...